Donatas Keras
Partner @ Practica Capital
Donatas Keras is a seed investor at Practica Capital focused on Software and Information Technology. Focus on investments, fundraising. Previously investment manager at MP Investment Bank, Nordic investment bank, and Middle Europe Investments Baltics, pan-Baltic RE investor, entrepreneur and investor.
- Total investments:
- 32
- Last investment:
- Lead investor:
- 78%
Last updated:
For AI agents: llms.txt
Industries Donatas Keras invests in
Stages Donatas Keras invests in
Countries Donatas Keras invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Software 7 (22%)
- Information Technology 5 (16%)
- Artificial Intelligence 5 (16%)
- B2B 4 (13%)
- E-Commerce 4 (13%)
Stage
- Seed 18 (56%)
- Series A 6 (19%)
- Pre-Seed 3 (9%)
- Venture - Series Unknown 1 (3%)
Country
- Lithuania 15 (47%)
- United Kingdom 3 (9%)
- United States 2 (6%)
- Canada 1 (3%)
- Latvia 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Kopa is the AI co-pilot for e-commerce brands — built on 9-figure operator expertise.We help digital stores grow faster with less effort by proactively analyzing every corner of the business — from marketing and inventory to pricing, reputation, and customer experience — then deploying AI agents to take action.We believe the future ofe-commerce isn’t just data-driven — it’s autonomous. And we’re building the invisible infrastructure to power it. | $2.3M / Seed / May 28, 2026 | ||
| Atrandi Biosciences, founded in 2016, is a pioneering life sciences tool company transforming single-cell analysis with its patented Semi-Permeable Capsule (SPC) technology. This next-generation technology isolates tens of thousands of single cells within discrete, permeable compartments, allowing bulk reactions to proceed as usual while preservingsingle-cell resolution. SPCs have already unlocked previously inaccessible applications, such as high-throughput microbial and eukaryotic genomics, and are poised to enable true single-cell multiomics. Headquartered in Vilnius, Lithuania, Atrandi’s name, meaning “you discover” in Lithuanian, embodies the company’s mission to empower scientists to uncover the unknown and make groundbreaking discoveries. | $25M / Series A / Feb 18, 2025 | ||
| Achieving compliance can be complicated and challenging, but it does not have to. AMLYZE offer fully integrated Transaction Monitoring, Risk Assessment & Case Management solutions making theses processes much easier and smoother for you. | $2.6M / Seed / Oct 02, 2024 | ||
| Biomatter is an enzyme design company creating previously impossible enzymes for health and sustainable manufacturing applications. We partner with leading companies across food, chemicals, home care, agriculture, diagnostics, and therapeutics to deliver new enzyme molecules — designed with AI and Physics, built and tested in our lab, in weeksrather than years. | $7.1M / Seed / Aug 05, 2024 | ||
| Spike Technologies, Inc., is a B2B data technology and artificial intelligence (AI) startup founded in 2022 and headquartered in Palo Alto, California. Spike provides API aggregation, data pipeline management (ETL), and a GenAI-driven tech to empower health data from wearables and IoT devices. Spike services clients in the digital health,professional fitness, insurance, and automation sectors. To learn more about Spike, please visit https://spikeapi.com/. | $3.5M / Seed / Jun 04, 2024 | ||
| Achieving compliance can be complicated and challenging, but it does not have to. AMLYZE offer fully integrated Transaction Monitoring, Risk Assessment & Case Management solutions making theses processes much easier and smoother for you. | $1.1M / Pre-Seed / May 18, 2023 | ||
| Atrandi Biosciences, founded in 2016, is a pioneering life sciences tool company transforming single-cell analysis with its patented Semi-Permeable Capsule (SPC) technology. This next-generation technology isolates tens of thousands of single cells within discrete, permeable compartments, allowing bulk reactions to proceed as usual while preservingsingle-cell resolution. SPCs have already unlocked previously inaccessible applications, such as high-throughput microbial and eukaryotic genomics, and are poised to enable true single-cell multiomics. Headquartered in Vilnius, Lithuania, Atrandi’s name, meaning “you discover” in Lithuanian, embodies the company’s mission to empower scientists to uncover the unknown and make groundbreaking discoveries. | $4.8M / Series A / Mar 28, 2023 | ||
| Oxipit research team consists of Kaggle-winning experienced deep learning engineers and radiologists.Oxipit offers a suite of Deep Learning chest X-ray image solutions: priority management, computer assisted diagnosis, pathology localization and visual search. Another area of work consists of tools for automatic head MRI/CT analysis –lesion segmentation, volumetric evaluation, localization relative to brain anatomy. | $4.2M / Series A / Jan 19, 2023 | ||
| Favro is the planning and collaboration app for organizational flow. It helps organizations do what they excel at - making products and services that change the game. Fast. | $322K / Seed / May 31, 2022 | ||
| Favro is the planning and collaboration app for organizational flow. It helps organizations do what they excel at - making products and services that change the game. Fast. | $4.3M / Seed / Dec 16, 2021 | ||
| See all 32 investments → | |||
Co-Investors
About Practica Capital
Practica Capital is an early-stage VC dedicated to backing Baltic founders. We have invested exclusively in tech potential in the Baltic States for the last 10 years. We back great founders in their ambition in seed and selected pre-seed and A stages partnering with them as company builders.Practica Capital manages three funds with €52M in AUM.To date, we have made more than 60 investments, including great companies like TransferGo, PVcase, Interactio, Eneba, Ovoko, Trafi, CGtrader, and others.We are the most active Baltic syndicate partner co-investing with local, regional, and international VCs & PEs, accelerators & incubators, angels, corporates, public agencies, banks, crowdfunding platforms, and others.
Practica Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anatolijus Faktorovicius
Partner
|
|||
Arvydas Bloze
Partner
|
|||
|
Donatas Keras
Partner
|
|||
Gintas Daniusevicius
Partner/CFO
|
|||
Lukas Borisovas
CMO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Donatas Keras invest in?
Donatas Keras invests primarily in Software, Information Technology and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 32 investments tracked by Shizune back companies in Lithuania. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Donatas Keras?
Public channels for Donatas Keras include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Donatas Keras last invest?
The most recent investment recorded for Donatas Keras closed in May 2026. Shizune tracks 32 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
